Table of Content

1 Secondary Progressive Multiple Sclerosis Drug Market Overview
1.1 Secondary Progressive Multiple Sclerosis Drug Product Scope
1.2 Secondary Progressive Multiple Sclerosis Drug Segment by Type
1.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016 & 2021 & 2027)
1.2.2 Inebilizumab
1.2.3 GLX-1112
1.2.4 DC-TAB
1.2.5 Etomoxir
1.2.6 IB-MS
1.2.7 Others
1.3 Secondary Progressive Multiple Sclerosis Drug Segment by Application
1.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Secondary Progressive Multiple Sclerosis Drug Market Estimates and Forecasts (2016-2027)
1.4.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Secondary Progressive Multiple Sclerosis Drug Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Secondary Progressive Multiple Sclerosis Drug Price Trends (2016-2027)

2 Secondary Progressive Multiple Sclerosis Drug Estimates and Forecasts by Region
2.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Secondary Progressive Multiple Sclerosis Drug Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2016-2021)
2.2.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2016-2021)
2.3 Global Secondary Progressive Multiple Sclerosis Drug Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Secondary Progressive Multiple Sclerosis Drug Estimates and Projections (2016-2027)
2.4.2 Europe Secondary Progressive Multiple Sclerosis Drug Estimates and Projections (2016-2027)
2.4.3 China Secondary Progressive Multiple Sclerosis Drug Estimates and Projections (2016-2027)
2.4.4 Japan Secondary Progressive Multiple Sclerosis Drug Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Estimates and Projections (2016-2027)
2.4.6 India Secondary Progressive Multiple Sclerosis Drug Estimates and Projections (2016-2027)

3 Global Secondary Progressive Multiple Sclerosis Drug Competition Landscape by Players
3.1 Global Top Secondary Progressive Multiple Sclerosis Drug Players by Sales (2016-2021)
3.2 Global Top Secondary Progressive Multiple Sclerosis Drug Players by Revenue (2016-2021)
3.3 Global Secondary Progressive Multiple Sclerosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Secondary Progressive Multiple Sclerosis Drug as of 2020)
3.4 Global Secondary Progressive Multiple Sclerosis Drug Average Price by Company (2016-2021)
3.5 Manufacturers Secondary Progressive Multiple Sclerosis Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Global Secondary Progressive Multiple Sclerosis Drug Market Size by Type
4.1 Global Secondary Progressive Multiple Sclerosis Drug Historic Market Review by Type (2016-2021)
4.1.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2016-2021)
4.1.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2016-2021)
4.1.3 Global Secondary Progressive Multiple Sclerosis Drug Price by Type (2016-2021)
4.2 Global Secondary Progressive Multiple Sclerosis Drug Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Type (2022-2027)
4.2.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Type (2022-2027)
4.2.3 Global Secondary Progressive Multiple Sclerosis Drug Price Forecast by Type (2022-2027)

5 Global Secondary Progressive Multiple Sclerosis Drug Market Size by Application
5.1 Global Secondary Progressive Multiple Sclerosis Drug Historic Market Review by Application (2016-2021)
5.1.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2016-2021)
5.1.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2016-2021)
5.1.3 Global Secondary Progressive Multiple Sclerosis Drug Price by Application (2016-2021)
5.2 Global Secondary Progressive Multiple Sclerosis Drug Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Application (2022-2027)
5.2.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Application (2022-2027)
5.2.3 Global Secondary Progressive Multiple Sclerosis Drug Price Forecast by Application (2022-2027)

6 North America Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures
6.1 North America Secondary Progressive Multiple Sclerosis Drug Sales by Company
6.1.1 North America Secondary Progressive Multiple Sclerosis Drug Sales by Company (2016-2021)
6.1.2 North America Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2016-2021)
6.2 North America Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type
6.2.1 North America Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2016-2021)
6.2.2 North America Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2022-2027)
6.3 North America Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application
6.3.1 North America Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application (2016-2021)
6.3.2 North America Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application (2022-2027)

7 Europe Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures
7.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Company
7.1.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Company (2016-2021)
7.1.2 Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2016-2021)
7.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type
7.2.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2016-2021)
7.2.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2022-2027)
7.3 Europe Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application
7.3.1 Europe 140 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 140 Sales Breakdown by Application (2022-2027)

8 China Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures
8.1 China Secondary Progressive Multiple Sclerosis Drug Sales by Company
8.1.1 China Secondary Progressive Multiple Sclerosis Drug Sales by Company (2016-2021)
8.1.2 China Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2016-2021)
8.2 China Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type
8.2.1 China Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2016-2021)
8.2.2 China Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2022-2027)
8.3 China Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application
8.3.1 China 168 Sales Breakdown by Application (2016-2021)
8.3.2 China 168 Sales Breakdown by Application (2022-2027)

9 Japan Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures
9.1 Japan Secondary Progressive Multiple Sclerosis Drug Sales by Company
9.1.1 Japan Secondary Progressive Multiple Sclerosis Drug Sales by Company (2016-2021)
9.1.2 Japan Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2016-2021)
9.2 Japan Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type
9.2.1 Japan Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2016-2021)
9.2.2 Japan Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2022-2027)
9.3 Japan Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application
9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures
10.1 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales by Company
10.1.1 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales by Company (2016-2021)
10.1.2 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2016-2021)
10.2 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type
10.2.1 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application
10.3.1 Southeast Asia K Pcs Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K Pcs Sales Breakdown by Application (2022-2027)

11 India Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures
11.1 India Secondary Progressive Multiple Sclerosis Drug Sales by Company
11.1.1 India Secondary Progressive Multiple Sclerosis Drug Sales by Company (2016-2021)
11.1.2 India Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2016-2021)
11.2 India Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type
11.2.1 India Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2016-2021)
11.2.2 India Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2022-2027)
11.3 India Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application
11.3.1 India Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application (2016-2021)
11.3.2 India Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Secondary Progressive Multiple Sclerosis Drug Business
12.1 AB Science SA
12.1.1 AB Science SA Corporation Information
12.1.2 AB Science SA Business Overview
12.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.1.4 AB Science SA Secondary Progressive Multiple Sclerosis Drug Products Offered
12.1.5 AB Science SA Recent Development
12.2 Actelion Ltd
12.2.1 Actelion Ltd Corporation Information
12.2.2 Actelion Ltd Business Overview
12.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Products Offered
12.2.5 Actelion Ltd Recent Development
12.3 Biogen, Inc.
12.3.1 Biogen, Inc. Corporation Information
12.3.2 Biogen, Inc. Business Overview
12.3.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Products Offered
12.3.5 Biogen, Inc. Recent Development
12.4 F. Hoffmann-La Roche Ltd.
12.4.1 F. Hoffmann-La Roche Ltd. Corporation Information
12.4.2 F. Hoffmann-La Roche Ltd. Business Overview
12.4.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.4.4 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Products Offered
12.4.5 F. Hoffmann-La Roche Ltd. Recent Development
12.5 Genzyme Corporation
12.5.1 Genzyme Corporation Corporation Information
12.5.2 Genzyme Corporation Business Overview
12.5.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Products Offered
12.5.5 Genzyme Corporation Recent Development
12.6 Glialogix, Inc.
12.6.1 Glialogix, Inc. Corporation Information
12.6.2 Glialogix, Inc. Business Overview
12.6.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Products Offered
12.6.5 Glialogix, Inc. Recent Development
12.7 Immune Response BioPharma, Inc.
12.7.1 Immune Response BioPharma, Inc. Corporation Information
12.7.2 Immune Response BioPharma, Inc. Business Overview
12.7.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Products Offered
12.7.5 Immune Response BioPharma, Inc. Recent Development
12.8 Innate Immunotherapeutics Ltd
12.8.1 Innate Immunotherapeutics Ltd Corporation Information
12.8.2 Innate Immunotherapeutics Ltd Business Overview
12.8.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Products Offered
12.8.5 Innate Immunotherapeutics Ltd Recent Development
12.9 Kyorin Pharmaceutical Co., Ltd.
12.9.1 Kyorin Pharmaceutical Co., Ltd. Corporation Information
12.9.2 Kyorin Pharmaceutical Co., Ltd. Business Overview
12.9.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Products Offered
12.9.5 Kyorin Pharmaceutical Co., Ltd. Recent Development
12.10 Mallinckrodt Plc
12.10.1 Mallinckrodt Plc Corporation Information
12.10.2 Mallinckrodt Plc Business Overview
12.10.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Products Offered
12.10.5 Mallinckrodt Plc Recent Development
12.11 MedDay SA
12.11.1 MedDay SA Corporation Information
12.11.2 MedDay SA Business Overview
12.11.3 MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.11.4 MedDay SA Secondary Progressive Multiple Sclerosis Drug Products Offered
12.11.5 MedDay SA Recent Development
12.12 MedImmune, LLC
12.12.1 MedImmune, LLC Corporation Information
12.12.2 MedImmune, LLC Business Overview
12.12.3 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.12.4 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Products Offered
12.12.5 MedImmune, LLC Recent Development
12.13 Merck KGaA
12.13.1 Merck KGaA Corporation Information
12.13.2 Merck KGaA Business Overview
12.13.3 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Products Offered
12.13.5 Merck KGaA Recent Development
12.14 Meta-IQ ApS
12.14.1 Meta-IQ ApS Corporation Information
12.14.2 Meta-IQ ApS Business Overview
12.14.3 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.14.4 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Products Offered
12.14.5 Meta-IQ ApS Recent Development
12.15 Novartis AG
12.15.1 Novartis AG Corporation Information
12.15.2 Novartis AG Business Overview
12.15.3 Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.15.4 Novartis AG Secondary Progressive Multiple Sclerosis Drug Products Offered
12.15.5 Novartis AG Recent Development
12.16 Opexa Therapeutics, Inc.
12.16.1 Opexa Therapeutics, Inc. Corporation Information
12.16.2 Opexa Therapeutics, Inc. Business Overview
12.16.3 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.16.4 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Products Offered
12.16.5 Opexa Therapeutics, Inc. Recent Development
12.17 Xenetic Biosciences (UK) Limited
12.17.1 Xenetic Biosciences (UK) Limited Corporation Information
12.17.2 Xenetic Biosciences (UK) Limited Business Overview
12.17.3 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
12.17.4 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Products Offered
12.17.5 Xenetic Biosciences (UK) Limited Recent Development

13 Secondary Progressive Multiple Sclerosis Drug Manufacturing Cost Analysis
13.1 Secondary Progressive Multiple Sclerosis Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Secondary Progressive Multiple Sclerosis Drug
13.4 Secondary Progressive Multiple Sclerosis Drug Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Secondary Progressive Multiple Sclerosis Drug Distributors List
14.3 Secondary Progressive Multiple Sclerosis Drug Customers

15 Market Dynamics
15.1 Secondary Progressive Multiple Sclerosis Drug Market Trends
15.2 Secondary Progressive Multiple Sclerosis Drug Drivers
15.3 Secondary Progressive Multiple Sclerosis Drug Market Challenges
15.4 Secondary Progressive Multiple Sclerosis Drug Market Restraints

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Secondary Progressive Multiple Sclerosis Drug Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
Table 2. Global Secondary Progressive Multiple Sclerosis Drug Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global Secondary Progressive Multiple Sclerosis Drug Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Region (2016-2021)
Table 5. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2016-2021)
Table 6. Global Secondary Progressive Multiple Sclerosis Drug Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Region (2016-2021)
Table 8. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) Forecast by Region (2022-2027)
Table 9. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Region (2022-2027)
Table 10. Global Secondary Progressive Multiple Sclerosis Drug Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share Forecast by Region (2022-2027)
Table 12. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) of Key Companies (2016-2021)
Table 13. Global Secondary Progressive Multiple Sclerosis Drug Sales Share by Company (2016-2021)
Table 14. Global Secondary Progressive Multiple Sclerosis Drug Revenue (US$ Million) by Company (2016-2021)
Table 15. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Company (2016-2021)
Table 16. Global Secondary Progressive Multiple Sclerosis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Secondary Progressive Multiple Sclerosis Drug as of 2020)
Table 17. Global Secondary Progressive Multiple Sclerosis Drug Average Price (USD/Pcs) of Key Company (2016-2021)
Table 18. Manufacturers Secondary Progressive Multiple Sclerosis Drug Manufacturing Sites and Area Served
Table 19. Manufacturers Secondary Progressive Multiple Sclerosis Drug Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Type (2016-2021)
Table 22. Global Secondary Progressive Multiple Sclerosis Drug Sales Share by Type (2016-2021)
Table 23. Global Secondary Progressive Multiple Sclerosis Drug Revenue (US$ Million) Market Share by Type (2016-2021)
Table 24. Global Secondary Progressive Multiple Sclerosis Drug Price (USD/Pcs) by Type (2016-2021)
Table 25. Global Secondary Progressive Multiple Sclerosis Drug Sales Share by Type (2022-2027)
Table 26. Global Secondary Progressive Multiple Sclerosis Drug Revenue (US$ Million) Market Share by Type (2022-2027)
Table 27. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Type (2022-2027)
Table 28. Global Secondary Progressive Multiple Sclerosis Drug Price (USD/Pcs) by Type (2022-2027)
Table 29. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Application (2016-2021)
Table 30. Global Secondary Progressive Multiple Sclerosis Drug Sales Share by Application (2016-2021)
Table 31. Global Secondary Progressive Multiple Sclerosis Drug Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global Secondary Progressive Multiple Sclerosis Drug Price (USD/Pcs) by Application (2016-2021)
Table 33. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Application (2022-2027)
Table 34. Global Secondary Progressive Multiple Sclerosis Drug Sales Share by Application (2022-2027)
Table 35. Global Secondary Progressive Multiple Sclerosis Drug Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Application (2022-2027)
Table 37. Global Secondary Progressive Multiple Sclerosis Drug Price (USD/Pcs) by Application (2022-2027)
Table 38. North America Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Company (2016-2021)
Table 39. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company (2016-2021)
Table 40. North America Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company (2016-2021)
Table 42. North America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2021) & (K Pcs)
Table 43. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2016-2021)
Table 44. North America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2022-2027) & (K Pcs)
Table 45. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2022-2027)
Table 46. North America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2021) & (K Pcs)
Table 47. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2016-2021)
Table 48. North America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2022-2027) & (K Pcs)
Table 49. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2022-2027)
Table 50. Europe Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Company (2016-2021)
Table 51. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company (2016-2021)
Table 52. Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company (2016-2021)
Table 54. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2021) & (K Pcs)
Table 55. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2016-2021)
Table 56. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2022-2027) & (K Pcs)
Table 57. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2022-2027)
Table 58. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2021) & (K Pcs)
Table 59. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2016-2021)
Table 60. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2022-2027) & (K Pcs)
Table 61. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2022-2027)
Table 62. China Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Company (2016-2021)
Table 63. China Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company (2016-2021)
Table 64. China Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2016-2021) & (US$ Million)
Table 65. China Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company (2016-2021)
Table 66. China Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2021) & (K Pcs)
Table 67. China Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2016-2021)
Table 68. China Secondary Progressive Multiple Sclerosis Drug Sales by Type (2022-2027) & (K Pcs)
Table 69. China Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2022-2027)
Table 70. China Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2021) & (K Pcs)
Table 71. China Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2016-2021)
Table 72. China Secondary Progressive Multiple Sclerosis Drug Sales by Application (2022-2027) & (K Pcs)
Table 73. China Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2022-2027)
Table 74. Japan Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Company (2016-2021)
Table 75. Japan Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company (2016-2021)
Table 76. Japan Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company (2016-2021)
Table 78. Japan Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2021) & (K Pcs)
Table 79. Japan Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2016-2021)
Table 80. Japan Secondary Progressive Multiple Sclerosis Drug Sales by Type (2022-2027) & (K Pcs)
Table 81. Japan Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2022-2027)
Table 82. Japan Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2021) & (K Pcs)
Table 83. Japan Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2016-2021)
Table 84. Japan Secondary Progressive Multiple Sclerosis Drug Sales by Application (2022-2027) & (K Pcs)
Table 85. Japan Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2022-2027)
Table 86. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Company (2016-2021)
Table 87. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company (2016-2021)
Table 88. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2016-2021) & (US$ Million)
Table 89. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company (2016-2021)
Table 90. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2021) & (K Pcs)
Table 91. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2016-2021)
Table 92. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales by Type (2022-2027) & (K Pcs)
Table 93. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2022-2027)
Table 94. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2021) & (K Pcs)
Table 95. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2016-2021)
Table 96. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales by Application (2022-2027) & (K Pcs)
Table 97. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2022-2027)
Table 98. India Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Company (2016-2021)
Table 99. India Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company (2016-2021)
Table 100. India Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2016-2021) & (US$ Million)
Table 101. India Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company (2016-2021)
Table 102. India Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2021) & (K Pcs)
Table 103. India Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2016-2021)
Table 104. India Secondary Progressive Multiple Sclerosis Drug Sales by Type (2022-2027) & (K Pcs)
Table 105. India Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2022-2027)
Table 106. India Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2021) & (K Pcs)
Table 107. India Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2016-2021)
Table 108. India Secondary Progressive Multiple Sclerosis Drug Sales by Application (2022-2027) & (K Pcs)
Table 109. India Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2022-2027)
Table 110. AB Science SA Corporation Information
Table 111. AB Science SA Description and Business Overview
Table 112. AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 113. AB Science SA Secondary Progressive Multiple Sclerosis Drug Product
Table 114. AB Science SA Recent Development
Table 115. Actelion Ltd Corporation Information
Table 116. Actelion Ltd Description and Business Overview
Table 117. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 118. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product
Table 119. Actelion Ltd Recent Development
Table 120. Biogen, Inc. Corporation Information
Table 121. Biogen, Inc. Description and Business Overview
Table 122. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 123. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 124. Biogen, Inc. Recent Development
Table 125. F. Hoffmann-La Roche Ltd. Corporation Information
Table 126. F. Hoffmann-La Roche Ltd. Description and Business Overview
Table 127. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 128. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product
Table 129. F. Hoffmann-La Roche Ltd. Recent Development
Table 130. Genzyme Corporation Corporation Information
Table 131. Genzyme Corporation Description and Business Overview
Table 132. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 133. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product
Table 134. Genzyme Corporation Recent Development
Table 135. Glialogix, Inc. Corporation Information
Table 136. Glialogix, Inc. Description and Business Overview
Table 137. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 138. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 139. Glialogix, Inc. Recent Development
Table 140. Immune Response BioPharma, Inc. Corporation Information
Table 141. Immune Response BioPharma, Inc. Description and Business Overview
Table 142. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 143. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 144. Immune Response BioPharma, Inc. Recent Development
Table 145. Innate Immunotherapeutics Ltd Corporation Information
Table 146. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 147. Innate Immunotherapeutics Ltd Description and Business Overview
Table 148. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product
Table 149. Innate Immunotherapeutics Ltd Recent Development
Table 150. Kyorin Pharmaceutical Co., Ltd. Corporation Information
Table 151. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 152. Kyorin Pharmaceutical Co., Ltd. Description and Business Overview
Table 153. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product
Table 154. Kyorin Pharmaceutical Co., Ltd. Recent Development
Table 155. Mallinckrodt Plc Corporation Information
Table 156. Mallinckrodt Plc Description and Business Overview
Table 157. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 158. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product
Table 159. Mallinckrodt Plc Recent Development
Table 160. MedDay SA Corporation Information
Table 161. MedDay SA Description and Business Overview
Table 162. MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 163. MedDay SA Secondary Progressive Multiple Sclerosis Drug Product
Table 164. MedDay SA Recent Development
Table 165. MedImmune, LLC Corporation Information
Table 166. MedImmune, LLC Description and Business Overview
Table 167. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 168. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product
Table 169. MedImmune, LLC Recent Development
Table 170. Merck KGaA Corporation Information
Table 171. Merck KGaA Description and Business Overview
Table 172. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 173. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product
Table 174. Merck KGaA Recent Development
Table 175. Meta-IQ ApS Corporation Information
Table 176. Meta-IQ ApS Description and Business Overview
Table 177. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 178. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product
Table 179. Meta-IQ ApS Recent Development
Table 180. Novartis AG Corporation Information
Table 181. Novartis AG Description and Business Overview
Table 182. Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 183. Novartis AG Secondary Progressive Multiple Sclerosis Drug Product
Table 184. Novartis AG Recent Development
Table 185. Opexa Therapeutics, Inc. Corporation Information
Table 186. Opexa Therapeutics, Inc. Description and Business Overview
Table 187. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 188. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 189. Opexa Therapeutics, Inc. Recent Development
Table 190. Xenetic Biosciences (UK) Limited Corporation Information
Table 191. Xenetic Biosciences (UK) Limited Description and Business Overview
Table 192. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 193. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product
Table 194. Xenetic Biosciences (UK) Limited Recent Development
Table 195. Production Base and Market Concentration Rate of Raw Material
Table 196. Key Suppliers of Raw Materials
Table 197. Secondary Progressive Multiple Sclerosis Drug Distributors List
Table 198. Secondary Progressive Multiple Sclerosis Drug Customers List
Table 199. Secondary Progressive Multiple Sclerosis Drug Market Trends
Table 200. Secondary Progressive Multiple Sclerosis Drug Market Drivers
Table 201. Secondary Progressive Multiple Sclerosis Drug Market Challenges
Table 202. Secondary Progressive Multiple Sclerosis Drug Market Restraints
Table 203. Research Programs/Design for This Report
Table 204. Key Data Information from Secondary Sources
Table 205. Key Data Information from Primary Sources
List of Figures
Figure 1. Secondary Progressive Multiple Sclerosis Drug Product Picture
Figure 2. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type in 2021 & 2027
Figure 3. Inebilizumab Product Picture
Figure 4. GLX-1112 Product Picture
Figure 5. DC-TAB Product Picture
Figure 6. Etomoxir Product Picture
Figure 7. IB-MS Product Picture
Figure 8. Others Product Picture
Figure 9. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application in 2021 & 2027
Figure 10. Hospital Examples
Figure 11. Clinic Examples
Figure 12. Others Examples
Figure 13. Global Secondary Progressive Multiple Sclerosis Drug Sales, (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2016-2027) & (US$ Million)
Figure 15. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) Growth Rate (2016-2027)
Figure 16. Global Secondary Progressive Multiple Sclerosis Drug Price Trends Growth Rate (2016-2027) (USD/Pcs)
Figure 17. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region: 2016 VS 2021
Figure 18. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region: 2021 VS 2027
Figure 19. North America Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 20. North America Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) Growth Rate (2016-2027)
Figure 21. Europe Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 22. Europe Secondary Progressive Multiple Sclerosis Drug Sales (Million USD) Growth Rate (2016-2027)
Figure 23. China Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 24. China Secondary Progressive Multiple Sclerosis Drug Sales (Million USD) and Growth Rate (2016-2027)
Figure 25. Japan Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 26. Japan Secondary Progressive Multiple Sclerosis Drug Sales (Million USD) Growth Rate (2016-2027)
Figure 27. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 28. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales (Million USD) Growth Rate (2016-2027)
Figure 29. India Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 30. India Secondary Progressive Multiple Sclerosis Drug Sales (Million USD) Growth Rate (2016-2027)
Figure 31. Global 5 Largest Secondary Progressive Multiple Sclerosis Drug Players Market Share by Revenue in Secondary Progressive Multiple Sclerosis Drug: 2016 & 2020
Figure 32. Secondary Progressive Multiple Sclerosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 33. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Type (2016-2021)
Figure 34. Global Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate by Type in 2016 & 2020
Figure 35. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Application (2016-2021)
Figure 36. Global Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate by Application in 2016 & 2020
Figure 37. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type in 2020
Figure 38. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application in 2020
Figure 39. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type in 2020
Figure 40. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application in 2020
Figure 41. China Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type in 2020
Figure 42. China Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application in 2020
Figure 43. Japan Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type in 2020
Figure 44. Japan Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application in 2020
Figure 45. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type in 2020
Figure 46. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application in 2020
Figure 47. India Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type in 2020
Figure 48. India Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application in 2020
Figure 49. Key Raw Materials Price Trend
Figure 50. Manufacturing Cost Structure of Secondary Progressive Multiple Sclerosis Drug
Figure 51. Manufacturing Process Analysis of Secondary Progressive Multiple Sclerosis Drug
Figure 52. Secondary Progressive Multiple Sclerosis Drug Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed